<p>In this episode of <strong>The BioHub Podcast</strong>, Max sits down with Cary Claiborne, CEO of Adial Pharmaceuticals.</p><p><br></p><p>Cary’s career spans finance, M&amp;A, and leadership across multiple public biotech companies before stepping into the CEO role at Adial. The company is focused on developing genetically targeted therapies for addiction, starting with alcohol use disorder.</p><p><br></p><p>In this conversation, Cary shares his transition into biotech leadership, what it’s like running a micro-cap clinical-stage company, and how Adial is approaching one of the most complex and underserved areas in medicine.</p><p><br></p><p>They also discuss leadership, resilience, and the realities of building and financing biotech companies in today’s market.</p><p></p>

The BioHub - by Avetix

Max Brennan - Biotech HeadHunter

Episode 142 - Cary Claiborne - CEO of Adial Pharma

APR 2, 202629 MIN
The BioHub - by Avetix

Episode 142 - Cary Claiborne - CEO of Adial Pharma

APR 2, 202629 MIN

Description

<p>In this episode of <strong>The BioHub Podcast</strong>, Max sits down with Cary Claiborne, CEO of Adial Pharmaceuticals.</p><p><br></p><p>Cary’s career spans finance, M&amp;A, and leadership across multiple public biotech companies before stepping into the CEO role at Adial. The company is focused on developing genetically targeted therapies for addiction, starting with alcohol use disorder.</p><p><br></p><p>In this conversation, Cary shares his transition into biotech leadership, what it’s like running a micro-cap clinical-stage company, and how Adial is approaching one of the most complex and underserved areas in medicine.</p><p><br></p><p>They also discuss leadership, resilience, and the realities of building and financing biotech companies in today’s market.</p><p></p>